Drugs / 64Cu-EB-ss-CPT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05891028 | May → Aug 2023 | colorectal cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-EB-ss-CPT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05891028 ↗ |
| Modality | Diagnostic / imaging agent | “Positron labeled camptothecin based PET imaging is a new imaging technique” NCT05891028 ↗ |
| Route | Intravenous | “64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans” NCT05891028 ↗ |